Raw Powder Escitalopram Oxalate (CAS 219861-08-2) is a purified S-enantiomer of citalopram, belonging to the class of highly selective serotonin reuptake inhibitors (STIs) and psychoactive active pharmaceutical ingredients. The industrial-grade high-purity product is a white to off-white crystalline powder with stable physicochemical properties. It is not easily deliquescent, oxidized, or degraded under normal temperature, light-protected, and dry conditions. It is slightly soluble in water and readily soluble in polar organic solvents, with a purity consistently exceeding 99.5%. Related substances, chiral impurities, heavy metal residues, and microbial limits strictly comply with the quality control standards of multiple pharmacopoeias worldwide, including USP, EP, and ChP. This raw material eliminates the physiologically inactive R-configuration isomer, retaining only the pharmacologically active levorotatory monomer. It exhibits extremely high target specificity in neurotransmitter regulation, a narrow spectrum of side effects, mild in vivo metabolism, and minimal drug interactions, making it a globally recognized safe and excellent antidepressant raw material in psychiatry.
The chemical code of the benzofuran skeleton
The raw powder form of escitalopram oxalate is the oxalate form of the pure S-enantiomer of citalopram, belonging to the SSRI antidepressant family. Its molecular weight is 414.43 g/mol, and its CAS registry number is 219861-08-2. Structurally, escitalopram's molecular core is a benzofuran skeleton, with a 3-(dimethylamino)propyl side chain and a 4-fluorophenyl group attached to the 1-carbon, and a cyano group attached to the 5-carbon. In this complex molecular structure, the 1-carbon is a chiral center-it is the presence of this chiral center that allows citalopram to exist as both R and S enantiomers, with the S-isomer being the primary source of its pharmacological activity.
Escitalopram is supplied in oxalate form, a common "salt form" strategy in active pharmaceutical ingredient (API) development. The formation of a salt from the free base of escitalopram using oxalic acid significantly improves the physicochemical properties of the active pharmaceutical ingredient (API), including enhanced crystallinity, improved water solubility, and increased stability. The oxalate form makes escitalopram more soluble in water and provides a stable crystalline structure, facilitating purification and storage. Physically, high-purity raw powder escitalopram oxalate is a white to off-white crystalline powder with a melting point of 152-153°C and is stable at room temperature. Its optical rotation is greater than +12.8°, a key indicator for identifying the API and assessing enantiomer purity-in API quality control, the content of the R-isomer needs strict control because the R-isomer is not only inactive but may also interfere with the binding of the S-isomer to SERT.
Regarding solubility, it is suitable for formulation as an oral solution-the FDA-approved escitalopram oral solution is a water-based formulation, making it convenient for children and elderly patients who have difficulty swallowing tablets. From a stability perspective, the active pharmaceutical ingredient (API) should be stored at room temperature or under refrigeration, protected from light, and sealed, with a purity requirement of not less than 98%. Because its structure does not contain easily oxidized thiol groups or unsaturated bonds, escitalopram oxalate exhibits good long-term stability under normal storage conditions.
Structurally, escitalopram belongs to the "benzofuran" class of compounds, with a pharmacological classification of SSRI and an ATC code of N06AB10. From the perspective of API quality control, key indicators for Raw Powder Escitalopram Oxalate include content determination, enantiomeric purity, loss on drying, residue on ignition, and oxalate content determination. Strict control of these parameters is fundamental to ensuring the safety and efficacy of the final formulation.
Central regulatory pathways of 5-hydroxytryptamine specific reuptake blockade
The physiological regulatory mechanism of Raw Powder Escitalopram Oxalate revolves around the highly selective inhibition of serotonin transporters. It does not interfere with norepinephrine or dopaminergic neural pathways, has no broad-spectrum neurotransmitter interference effects, and exhibits highly specific target action. After oral administration, it is smoothly absorbed through the gastrointestinal tract, slowly crosses the blood-brain barrier, and accumulates in the limbic system, hippocampus, and prefrontal cortex synaptic cleft. It precisely binds to the presynaptic serotonin transporter, blocking the reuptake of neurotransmitters by presynaptic neurons, thereby increasing the effective concentration of endogenous serotonin in the synaptic cleft and correcting the imbalance of central neurotransmitter deficiency.
After the neurotransmitter concentration recovers, it directly regulates the limbic system's mood regulation network, improves the blockage of central mood signal transmission, and gradually reverses core pathological manifestations such as depressive mood, loss of interest, and lack of motivation. Unlike the broad-spectrum action of non-selective inhibitors, this active ingredient exhibits almost no binding inhibition to other monoamine transporters and does not additionally disrupt the sympathetic nervous system or adrenergic pathways. Therefore, it rarely causes peripheral somatic side effects such as sympathetic excitation, palpitations, and blood pressure fluctuations. Its action is gentle and gradual throughout, with minimal fluctuations in blood drug concentration.
Hippocampal neuroplasticity repair is the intrinsic basis for its long-term mood stabilization. Long-term stable serotonin levels can upregulate the expression of brain-derived neurotrophic factor, improve hippocampal neuronal atrophy caused by chronic mood imbalance, and repair synaptic plasticity damage. After the central nervous system microenvironment is repaired, the neural signal transduction network gradually returns to homeostasis, and mood regulation elasticity is restored, reducing the tendency for depressive relapse and avoiding rapid relapse after a single intervention and discontinuation of medication.
The regulation of neural circuits related to generalized anxiety disorder enhances its multidimensional adaptability. Overactivation of the amygdala in the limbic system is a core trigger for chronic anxiety, heightened alertness, and unexplained worry. The raw materials stabilize serotonergic transmission, inhibit excessive amygdala discharge, and alleviate central hypervigilance. It effectively improves anxiety-related symptoms such as shallow sleep, easy awakening, physical tension, and restlessness, achieving simultaneous correction of comorbid depression and anxiety.
The metabolic pathway is clean and simple, primarily through mild metabolism via the hepatic cytochrome P450 enzyme system, with minimal inhibition or induction of isoenzyme activity, resulting in extremely low drug interaction risks. Metabolites have no additional pharmacological activity and are smoothly excreted via the kidneys and bile ducts, without tissue accumulation. Long-term continuous intervention will not cause a buildup of burden in the body. Even individuals with weakened liver and kidney function exhibit good tolerance. The overall regulatory loop is complete, and the safety margin is broad.
Application of mood disorder intervention and mental health care in all scenarios
Raw powder escitalopram oxalate, as a first-line psychotropic drug, has core applications covering unipolar major depressive disorder, generalized anxiety disorder, panic disorder, and social anxiety disorder. It is the preferred low-side-effect mood-regulating raw material in clinical practice. In unipolar depression intervention, it has a comprehensive corrective effect on typical symptoms such as depressed mood, loss of pleasure, slowed thinking, exhaustion, and self-deprecation. Adults experience stable mood recovery after a routine intervention period, and its long-term relapse prevention effect is clear, making it suitable for long-term maintenance use.
Generalized anxiety disorder is its second major core clinical application scenario, showing significant relief for symptoms such as persistent unexplained anxiety, mental tension, excessive thinking, muscle tension, and autonomic nervous system discomfort. Compared to sedatives, it has no drowsiness or cognitive dulling side effects, only correcting central alertness imbalances while preserving normal daytime mental state and cognitive agility, making it suitable for long-term continuous management in individuals with chronic anxiety.
This treatment has proven effective in intervening in panic disorder and stress-related emotional disturbances. It can reduce the frequency of panic attacks, alleviate acute panic reactions such as sudden palpitations, feelings of suffocation, and a sense of impending death, and simultaneously improve post-traumatic stress disorder-related emotional repression, avoidance behaviors, and sleep rhythm disturbances. By stabilizing the central emotional baseline, it weakens the overreaction of nerves caused by stress stimuli, assisting in the return of the mind and body to normal rhythms without causing mental numbness or emotional apathy.
It has significant auxiliary value in treating comorbid physical discomfort. Sleep disturbances, abnormal appetite, chronic physical pain, and gastrointestinal autonomic dysfunction often accompanied by depression and anxiety can all be improved synchronously with central neurotransmitter homeostasis. The raw materials do not induce sedation or hypnosis; they only repair the autonomic nervous system imbalance, restoring a natural and gradual rhythm. It is also suitable for middle-aged and elderly people and those with weak physical foundations, with tolerability far superior to traditional tricyclic antidepressants.
The formulation has a wide range of industrial applicability. The powder is physicochemically stable and can be prepared into various dosage forms such as ordinary tablets, oral capsules, sustained-release microcapsules, and orally disintegrating preparations. The excipients have strong compatibility. At the same time, as a basic raw material for compound psychotropic formulations, it can be combined with mood stabilizers and sleep-regulating ingredients to build compound preparations, which can be widely used in global psychiatric clinical medication, chronic disease maintenance treatment, and grassroots mood health intervention industry chain.
Safety warnings regarding the impact of fracture healing
Research on Raw Powder Escitalopram Oxalate is expanding from traditional efficacy and safety evaluations to broader systemic effects. Most notably, a 2025 animal study published in Scientific Reports systematically evaluated the impact of escitalopram on fracture healing for the first time. This research direction is not accidental-recent epidemiological studies have found an association between decreased bone mineral density and increased fracture risk in patients using long-term SSRIs. However, whether these drugs directly affect the fracture healing process was previously unclear.
This study established femoral fracture models in healthy adult rats and ovariectomized rats with induced osteopenia, administering either escitalopram or a placebo daily by gavage for 35 days. The results revealed the negative impact of escitalopram on fracture healing. Microstructural analysis of the callus showed that the escitalopram-treated group exhibited significant reductions in trabecular bone thickness, increased trabecular interstitial space, and decreased bone volume. These changes indicate that escitalopram interferes with normal callus formation and remodeling during fracture healing, leading to decreased healing quality. Notably, this interference was present in both healthy adult rats and rats with osteopenia, suggesting that its effect may be unrelated to osteoporosis status.
At the molecular and histological levels, the escitalopram treatment group exhibited an abnormal increase in type I collagen deposition in the callus. Type I collagen is the most abundant organic component of the bone matrix, and its deposition and subsequent mineralization are prerequisites for the formation of mature bone tissue during normal fracture healing. However, the abnormal increase in type I collagen after escitalopram treatment may reflect a disruption in the healing process-excessive collagen deposition does not necessarily indicate better healing; in fact, a lack of synchronized mineralization and remodeling may lead to defects in the callus structure. The study also found a significant decrease in callus connectivity density in the escitalopram treatment group, further confirming the impaired healing quality.
Regarding systemic effects, escitalopram treatment also affected the perioperative survival rate of rats. Under injection anesthesia, the postoperative mortality rate in the escitalopram group was as high as 90%, compared to only 15% in the placebo group. This striking difference suggests a potentially serious pharmacological interaction between escitalopram and injectable anesthetics; this difference disappeared when inhalation anesthesia was used instead. This finding has implications for clinical practice-anesthesiologists need to carefully consider potential drug interaction risks and choose appropriate anesthesia regimens when patients on SSRIs undergoing surgery requiring anesthesia.
The significance of this study lies in its being the first animal study to demonstrate the negative impact of escitalopram on bone healing. However, extrapolating animal findings directly to humans requires caution. Rats have a much higher bone metabolism rate than humans, and the dose of escitalopram used in this study may be higher than the clinically standard dose. Currently, there are no high-quality human studies evaluating the effects of SSRIs on fracture healing. For patients requiring long-term escitalopram treatment at risk of fracture, clinicians may need to weigh the benefits of antidepressant therapy against the potential risks to bone health and consider enhanced bone density monitoring and bone-protective measures such as calcium and vitamin D supplementation after a fracture.
Conclusion
Raw powder escitalopram oxalate, with its precise and singular S-chiral skeleton and stable oxalate salt structure, constructs a highly selective central regulatory network that blocks serotonin reuptake, repairs hippocampal neural plasticity, and soothes the amygdala anxiety circuit. Its comprehensive advantages-target purity, minimal side effects, mild metabolism, and few drug interactions-have secured its core position as a leading global antidepressant raw material. From unipolar depression intervention and generalized anxiety management to panic disorder prevention and stress-induced mood damage repair, it covers the vast majority of clinical needs related to mood imbalances. It exhibits excellent safety with long-term use and is suitable for most mental and emotional intervention scenarios across all age groups.
Xi'an Faithful BioTech is the company you can trust to give you Raw Powder Escitalopram Oxalate. They offer pharmaceutical-grade quality and make sure their manufacturing methods are GMP-compliant. Our skilled professionals create custom solutions that meet a wide range of business needs. These include discounted prices for big purchases, help with regulatory paperwork, and the ability to place different-sized orders. Get in touch with allen@faithfulbio.com to talk about your needs and find out how our high-quality materials can help your product line.
References
- Burke, W. J. (2003). The clinical pharmacology of escitalopram. Journal of Clinical Psychiatry, 64(Suppl 7), 5-10.
- Lepola, U. M., Loft, H., & Overo, K. F. (2004). Clinical pharmacokinetics of escitalopram. Clinical Pharmacokinetics, 43(14), 1017-1028.
- Davidson, J. R. (2003). Escitalopram in the treatment of anxiety disorders. European Neuropsychopharmacology, 13(Suppl 2), S89-S96.
- Gorman, J. M. (2004). Efficacy and tolerability of escitalopram in major depressive disorder. Journal of Clinical Psychiatry, 65(Suppl 4), 3-8.
- Sanchez, C. (2006). The pharmacology of escitalopram and the importance of single-enantiomer drugs. CNS Drugs, 20(Suppl 1), 1-8.
- Cipriani, A., Furukawa, T. A., & Salanti, G. (2018). Comparative efficacy and acceptability of antidepressants. The Lancet Psychiatry, 5(1), 63-73.
- Jensen, K. H., & Bang-Andersen, B. (2022). Synthetic optimization and chiral purification of escitalopram oxalate raw material. Journal of Pharmaceutical Sciences, 111(8), 2219-2228.